Floatz Rating
CC40/100
Confidence
Indicative
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05694364CT.gov Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prgn-3007 (this asset) | H. Lee Moffitt Cancer Center and Research Institute | P1 | CC · 40 |
| Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Equine Atg | Instituto Nacional de Cancer, Brazil | P3 | BBB |
| Thioguanine Anhydrous | St. Jude Children's Research Hospital | P4 | BBB |
| Mercaptopurine Anhydrous | Dana-Farber Cancer Institute | P4 | BB |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Asparaginase | Centre Hospitalier Universitaire de Nice | P4 | BB |
| Methotrexate | Princess Maxima Center for Pediatric Oncology | P4 | BB |
+42 more in the Acute Lymphoblastic Leukemia cohort
Other indications for Prgn-3007
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P1 | CC · 47 |
| Diffuse Large B-Cell Lymphoma | — | P1 | CC · 42 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P1 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Peripheral Blood Stem Cells, Allogeneic, Cd34 PositiveFred Hutchinson Cancer CenterBBB
- Gm-CsfXinhua Hospital, Shanghai Jiao Tong University School of MedicineBBB
- Equine AtgInstituto Nacional de Cancer, BrazilBBB
- Thioguanine AnhydrousSt. Jude Children's Research HospitalBBB
- Mercaptopurine AnhydrousDana-Farber Cancer InstituteBB
Citation
Floatz Terminal. Prgn-3007 in Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prgn-3007-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →